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Acute disseminated encephalomyelitis in children: 
differential diagnosis from multiple sclerosis on the 
basis of clinical course
Acute disseminated encephalomyelitis (ADEM) is a demyelinating 
disease of the central nervous system (CNS) that typically presents 
as a monophasic disorder associated with multifocal neurologic 
symptoms and encephalopathy. ADEM is considered an autoimmune 
disorder that is triggered by an environmental stimulus in genetically 
susceptible individuals. The diagnosis of ADEM is based on clinical 
and radiological features. Most children with ADEM initially present 
with fever, meningeal signs, and acute encephalopathy. The level 
of consciousness ranges from lethargy to frank coma. Deep and 
subcortical white-matter lesions and gray-matter lesions such as 
thalami and basal ganglia on magnetic resonance imaging (MRI) 
are associated with ADEM. In a child who presents with signs of 
encephalitis, bacterial and viral meningitis or encephalitis must be 
ruled out. Sequential MRI is required to confirm the diagnosis of 
ADEM, as relapses with the appearance of new lesions on MRI 
may suggest either multiphasic ADEM or multiple sclerosis (MS). 
Pediatric MS, defined as onset of MS before the age of 16, is being 
increasingly recognized. MS is characterized by recurrent episodes of 
demyelination in the CNS separated in space and time. The McDonald 
criteria for diagnosis of MS include evidence from MRI and allow the 
clinician to make a diagnosis of clinically definite MS on the basis of 
the interval preceding the development of new white matter lesions, 
even in the absence of new clinical findings. The most important 
alternative diagnosis to MS is ADEM. At the initial presentation, the 2 
disorders cannot be distinguished with certainty. Therefore, prolonged 
follow-up is needed to establish a diagnosis.
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Introduction
Acute disseminated encephalomyelitis (ADEM) is an immune 
mediated disease of the central nervous system (CNS) that produces 
multiple inflammatory lesions in the brain and spinal cord, parti-
cularly in the white matter. ADEM should be distinguished from 
other central inflammatory demyelinating disorders of children, 
including multiple sclerosis (MS) and clinically isolated syndromes 
that include optic neuritis, transverse myelitis, and neuromyelitis 
optica (Devic's disease). Most of these disorders are thought to be 
caused by immune system dysregulation triggered by an infectious or 
other environmental agent in a genetically susceptible host.
ADEM is often preceded by a viral or bacterial infection, usually 
in the form of a nonspecific upper respiratory infection. In 3 previous 
studies, an antecedent infection was identified in 72 to 77 percent of 
ADEM patients
1-3). In general, patients will present within 1 month of 
this initial illness. Numerous causative pathogens have been identified 
to date. Viruses that have been implicated include coronavirus, 
coxsackie virus, cytomegalovirus, Epstein-Barr virus, herpes simplex 
virus, hepatitis A virus, human immunodeficiency virus, influenza 
virus, measles virus, rubella virus, varicella zoster virus, and West Nile 
virus
4-11). Other organisms associated include Borrelia burgdorferi, 
Chlamydia, Leptospira, Mycoplasma pneumoniae, Rickettsia, and 
beta-hemolytic Streptococcus
4,12).
Less than 5 percent of all ADEM cases follow immunization. 
Postvaccinal ADEM has been associated with immunization for 
rabies, hepatitis B, influenza, Japanese B encephalitis, diphtheria/
pertussis/tetanus, measles, mumps, rubella, pneumococcus, polio, 
smallpox, and varicella
12). No infectious agent is isolated in most 
cases. Currently, measles, mumps, and rubella vaccination are most 
often associated with postvaccination ADEM. It is important to 
recognize the significant difference between the incidence of ADEM 
associated with the live measles vaccination (1 to 2 per million) and 
the incidence of ADEM previously associated with the measles virus 
infection (1 in 1,000)
13). 
The pathogenesis of ADEM is incompletely understood. The 
proposed mechanism of ADEM is that myelin autoantigens, such as 
myelin basic protein, proteolipid protein, and myelin oligodendrocyte 
protein, share antigenic determinants with those of an infecting 
pathogen
12). This model is supported by studies of lymphocytes in 
children with ADEM. In 1 report, the frequency of T cell reactivity 
to myelin basic protein was 10 times higher in patients with ADEM 
than in those with encephalitis or normal controls
5). 
MS is usually thought to be a disease of young adults. However, 
pediatric MS, defined as onset of MS before the age of 16, is 
being increasingly recognized. MS presents before the age of 16 
in approximately 5 percent of patients
14,15). In less than 1 percent 
of patients, the onset of MS occurs before the age of 10 years
16). 
In addition, pediatric MS affects girls more than boys, with a 
female to male ratio of 2.8
17). Since pediatric MS is rare, a child 
with recurrent episodes of acute neurologic symptoms and white 
matter lesions on magnetic resonance imaging (MRI) might be 
originally misdiagnosed with one of several other disorders, including 
leukodystrophies, vasculopathies, lymphoma, mitochondrial defects, 
and other metabolic disorders, rather than MS. 
Clinical features 
Neurologic symptoms of ADEM commonly appear 4 to 13 days 
after the infection or vaccination
1-3). Fever, headache, vomiting, 
and meningismus are often seen at the time of initial presentation 
and may persist during hospitalization
2,18). Encephalopathy is a 
characteristic feature and may progress rapidly in association with 
multifocal neurologic deficits
4). Progression of initial neurologic signs 
to maximum deficits usually occurs within 4 to 7 days
1,3). The level of 
consciousness ranges from subtle lethargy to frank coma. The altered 
mental status often raises concern regarding the risk of seizures, 
although these occur in only one-third of patients
3,19).  
In addition to encephalopathy, the most common neurologic 
features of ADEM include long tract (pyramidal tract) signs, acute 
hemiparesis, cerebellar ataxia, cranial neuropathies, including 
optic neuritis, and spinal cord dysfunction (transverse myelitis)
2-4,18, 
19). Symptoms of optic neuritis include vision loss, pain with eye 
movement, and an afferent pupillary defect. Inflammation of the 
optic disc may be seen by direct funduscopic examination if there is 
extensive involvement of the optic nerve. The imaging of the optic 
nerve with a gadolinium-enhanced MRI of the brain and orbits is 
a more sensitive means to diagnose optic neuritis in these patients. 
Symptoms of transverse myelitis include flaccid paralysis of the legs 
with a change in sensory level on examination. Bowel and bladder 
involvement secondary to spinal cord disease results in constipation 
and urinary retention. The arms can be involved if the demyelinating 
lesion affects the cervical cord. Respiratory failure may appear 
with high cervical lesions that extend into the brainstem. Aphasia, 
movement disorders, and sensory deficits are unusual. The severe 
phase of ADEM generally lasts from 2 to 4 weeks. Children may 
show deterioration in their condition after hospital admission, and 
most of them develop new neurologic signs. Patients usually recover 
completely from the acute illness, although some have neurologic 
sequelae. 
MS is a clinical diagnosis and is characterized by spatially and 
temporally distinct recurrent episodes of demyelination in the CNS. 236      YJ Lee • Acute disseminated encephalomyelitis in children
Acute inflammation and demyelination in a critical area of the brain, 
optic nerves, or spinal cord can induce a corresponding neurologic 
deficit. There are no clinical signs that are unique to this disorder, but 
some are highly characteristic (Table 1)
20). Common symptoms of 
MS are listed in Table 2
20). A European observational study of 394 
children with pediatric-onset MS and 1,775 patients with adult-onset 
MS showed that children were more likely than adults to present with 
isolated optic neuritis, an isolated brainstem syndrome, or symptoms 
of encephalopathy
17).
A clinically isolated syndrome (CIS) is defined as a single mono-
symptomatic attack compatible with MS, such as optic neuritis. An 
episode of CIS can produce diagnostic and therapeutic dilemmas (Fig. 
1), since the vast majority of children will not have a recurrence after 
a single demyelinating event of the CNS. The value of examinations, 
including brain MRI, cerebrospinal fluid (CSF) analyses, and other 




The diagnosis of ADEM is based on clinical and radiological 
features
4). There is no specific biological marker or confirmatory 
test. ADEM should be suspected in a child who develops multifocal 
neurologic abnormalities with encephalopathy (e.g., confusion, 
excessive irritability, or an altered level of consciousness), especially if 
onset occurs one to two weeks after a viral infection or vaccination. 
The MRI abnormalities seen in ADEM are best defined using T2-
weighted images and fluid-attenuated inversion recovery (FLAIR) 
sequences (Fig. 2). Contrast enhancement is sometimes seen in 
acute lesions. Lesions associated with ADEM are typically bilateral 
but may be asymmetric and tend to be poorly marginated. Almost 
all patients have multiple lesions in the deep and subcortical white 
matter, while the periventricular white matter is generally spared. The 
thalami and basal ganglia are frequently affected (Fig. 2), and lesions 
in these locations are often symmetrical
3,22). Brainstem and spinal 
cord abnormalities on MRI are common in ADEM
12). The number 
of lesions varies, and their diameters range from <5 mm to 5 cm
1,3). 
Table 1. Clinical Features of Multiple Sclerosis
Features suggestive of multiple sclerosis
   Relapses and remissions
   Onset between ages 15 and 50
   Optic neuritis
   Lhermitte’s sign
   Internuclear ophthalmoplegia
   Fatigue
   Uhthoff’s phenomenon
Features not suggestive of multiple sclerosis
   Steady progression
   Onset before age 10 or after age 50
   Cortical deficits such as aphasia, apraxia, alexia, neglect
   Rigidity, sustained dystonia
   Convulsions
   Early dementia
   Deficit developing within minutes
Fig. 1. Diagnosis of a demyelinating clinical event. ADEM, acute 
disseminated encephalomyelitis; CIS, clinically isolated syndrome; 
MRI, magnetic resonance imaging; MDEM, multiphase disseminated 
encephalomyelitis; MS, multiple sclerosis; NMO, neuromyelitis optica; 
ON, optic neuritis; TM, transverse myelitis.
Table 2. Presenting Symptoms in Multiple Sclerosis 
Symptoms Female  Male Total 
Sensory in limbs 33.2 25.1 30.7
Visual loss 16.3 15.1 15.9
Motor (subacute) 8.3 10.4 8.9
Diplopia 6.0 8.5 6.8
Gait disturbance 3.2 8.3 4.8
Motor (acute) 4.4 4.2 4.3
Balance problems 2.5 4.0 2.9
Sensory in face 2.9 2.5 2.8
Lhermitte's sign (electric shock-like sensations 
that run down the back and/or limbs upon 
flexion of the neck)
1.6 2.3 1.8
Vertigo 1.8 1.5 1.7
Bladder problems 0.9 1.1 1.0
Limb ataxia 0.9 1.3 1.0
Acute transverse myelopathy 0.8 0.6 0.7
Pain 0.3 0.8 0.5
Other 2.6 2.5 2.5
Polysymptomatic onset 14.5 11.9 13.7
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In the spinal cord, large confluent intramedullary lesions that extend 
over multiple segments are common
3,12), and the degree of contrast 
enhancement is variable. Abnormal findings on MRI may progress 
over a relatively short period of time, consistent with progression 
of the disease. Sequential imaging by MRI is sometimes required 
to confirm the diagnosis of ADEM, as the occurrence of relapses, 
with new lesions on MRI, is not compatible with a diagnosis of 
monophasic ADEM, and suggests that the correct diagnosis is either 
multiphasic ADEM or MS, based upon the clinical symptoms and 
neuroimaging findings
4). 
Analysis of CSF reveals pleocytosis and/or increased protein 
concentration in the majority of patients with ADEM
1,2). However, 
the CSF can also be normal. Oligoclonal bands in CSF are seen in 
some patients with ADEM, but are a nonspecific finding more often 
associated with multiple sclerosis. Evaluation for infectious agents 
includes viral cultures of samples from the throat and nasopharynx, 
stool, and CSF, and serologic testing for influenza, Epstein-Barr virus, 
herpes, varicella, mycoplasma, cytomegalovirus, and rubella. These 
studies are rarely positive
12).
Diagnostic criteria for ADEM in children have been proposed by 
the International Pediatric Multiple Sclerosis Study Group (Table 
3)
23). The major criteria are a clinical attack of CNS demyelinating 
disease with acute or subacute onset, polysymptomatic neurologic 
features, and encephalopathy. Encephalopathy as a presenting 
symptom is essential for a diagnosis of ADEM, according to the 
Study Group criteria
23). Encephalopathy is defined as including either 
behavioral changes, such as lethargy or irritability, or more severe 
alterations in the level of consciousness, such as coma. The onset of 
Fig. 2. (A) An axial fluid-attenuated inversion recovery magnetic resonance imaging (MRI) 
of the brain in a child with acute disseminated encephalo  pmyelitis demonstrates multifocal 
areas of hyperintensity in both cerebral hemispheres involving cortical gray matter, centrum 
semiovale, and deep gray nuclei. (B) A saggital T2-weighted MRI of the spine in the same 
child demonstrates high signal intrinsic to the spinal cord, consistent with longitudinally 
extensive transverse myelitis. 
A B
Table 3. Diagnostic Criteria of Acute Disseminated Encephalomyelitis 
(ADEM)
Clinical features
First clinical attack of inflammatory or demyelinating disease in the CNS
Acute or subacute onset
Affects multifocal areas of the CNS 
Polysymptomatic presentation
Must include encephalopathy:
Acute behavioral change such as confusion or irritability and/or
Alteration in consciousness ranging from somnolence or coma
Attack should be followed by improvement on clinical and/or neuro-
radiologic (MRI) measures
Sequelae may include residual deficits
No other etiologies can explain the event
ADEM relapses (with new or fluctuating symptoms, signs or MRI findings) 
occurring within three months of the inciting ADEM episode are 
considered part of the same acute event. In addition, ADEM relapses 
that occur during a steroid taper or within four weeks of completing a 
steroid taper are considered part of the initial inciting ADEM episode.
Lesion Characteristics on MRI FLAIR and T2 weighted images
Large (>1 to 2 cm in size) multifocal, hyperintense, bilateral, asymmetric 
lesions in the supratentorial or infratentorial white matter. Rarely, brain 
MRI shows a single large (≥1 to 2 cm) lesion predominantly affecting 
white matter.
Gray matter, especially basal ganglia and thalamus, may be involved
Spinal cord MRI may show confluent intramedullary lesion(s) with variable 
enhancement, in addition to the abnormalities on brain MRI
No radiologic evidence of previous destructive white matter changes
Encephalopathy is a required feature for the diagnosis of ADEM, but is 
not a typical feature of multiple sclerosis. In addition, a cerebrospinal fluid 
pleocytosis ≥50 white blood cells/mm can be observed in ADEM, whereas 
this finding is highly atypical for multiple sclerosis. CNS, central nervous 
system; MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion 
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encephalopathy almost directly corresponds to the occurrence of the 
disease state. This feature helps to differentiate ADEM from other 
clinically isolated syndromes that are related to recurrence of MS 
and will lead to a subsequent MS diagnosis. Brain MRI criteria for 
ADEM diagnosis include focal or multifocal lesions predominantly 
involving the white matter, without evidence of previous white-matter 
changes.
The diagnostic criteria can also distinguish between monophasic 
ADEM with early relapses, and recurrent forms of ADEM
23) on the 
basis of the following conditions: 
- A single clinical episode of ADEM, monophasic ADEM, may 
evolve over as long as 3 months
23). Any new and fluctuating symp-
toms occurring within 3 months of the initial event are con  sidered to 
be part of the same event. In addition, symptoms that appear during 
tapering of glucocorticoid therapy, or within 1 month of completing 
a glucocorticoid taper, are considered to be part of the same episode. 
- Recurrent ADEM refers to the recurrence, 3 or more months 
after the first ADEM event, of the same symptoms that occurred at 
the time of the initial presentation. The MRI findings are similar to 
those seen at the initial event and are without new lesions, although 
there may be enlargement of the original lesions. 
- Multiphasic ADEM describes recurrent disease that fulfills cri-
teria for ADEM but involves new anatomic areas of the CNS upon 
recurrence. Symptoms and signs are different from those in the initial 
event. The MRI must show new lesions not present during the first 
attack and demonstrate complete or partial resolution of the lesions 
associated with the first ADEM episode.
Diagnosis of pediatric MS
Until 2006, the Poser criteria were considered the most useful in 
making a diagnosis of pediatric MS
24). In 2007, the Pediatric Multiple 
Sclerosis Study Group proposed new working definitions for 
pediatric MS and related demyelinating diseases such as ADEM
23). 
The working group suggested use of the 2001 McDonald Criteria 
to make a diagnosis of pediatric MS
25). The McDonald criteria 
integrate MRI findings and allow the physician to make a diagnosis 
of clinically definite MS based upon the time interval preceding 
the development of new white matter lesions, even in the absence 
of new clinical findings (Tables 4, 5)
25,26). The McDonald criteria 
for dissemination in space (Table 4) specify a minimal number of 
lesions, with or without MRI contrast enhancement, being present 
in specific areas of the CNS including periventricular, juxtacortical, 
infratentorial, and spinal cord regions.
The McDonald criteria were revised in 2005 for adult-onset MS
26), 
but these revisions have not been applied to pediatric MS. A main 
difference between the revised McDonald criteria and the 2007 
Study Group criteria for pediatric MS concerns the time required 
between clinical attacks or the development of new MRI lesions 
to qualify for the "dissemination in time." The revised McDonald 
criteria require a minimum of only 30 days to elapse prior to the 
development of a new MRI lesion to qualify as dissemination in time, 
Table 4. International Panel on Multiple Sclerosis (MS) Diagnostic Criteria 
Clinical presentation Additional data needed for MS diagnosis
≥2 attacks; objective clinical evidence of ≥2 lesions None (however, if tests such as MRI or CSF analysis are undertaken and are negative, extreme caution 
should be taken before making the diagnosis). 
Alternative diagnoses must be considered and there must be no better explanation for the clinical 
procedure.
≥2 attacks; objective clinical evidence of 1 lesion Dissemination in space, demonstrated by: MRI* or ≥ 2 MRI-detected lesions consistent with MS plus 
positive CSF (determined by oligoclonal bands that are different from any such bands in the serum, or 
by a raised immunoglobulin G index) or await further clinical attack implicating a different site
One attack; objective clinical evidence of ≥2 lesions Dissemination in time, demonstrated by: MRI† or second clinical attack
One attack; objective clinical evidence of one lesion 
(monosymptomatic presentation; clinically isolated 
syndrome)
Dissemination in space, demonstrated by: MRI* or ≥2 MRI-detected lesions consistent with MS plus 
positive CSF as defined above and
Dissemination in time, demonstrated by: MRI
† or second clinical attack implicating a different site
Insidious neurological progression suggestive of MS Positive CSF as defined above and 
Dissemination in space, demonstrated by: ≥9 T2 lesions in the brain or 2 or more lesions in the spinal 
cord or 4 to 8 brain plus 1 spinal cord lesion or abnormal visual evoked potential (delay with a well 
preserved wave form, typical of MS) associated with 4 to 8 brain lesions or with fewer than 4 brain 
lesions plus 1 spinal cord lesion demonstrated by MRI and
Dissemination in time, demonstrated by: MRI
† or continued progression for 1 year
MRI, magnetic resonance imaging; CSF, cerebrospinal fluid; MS, multiple sclerosis.
*MRI criteria include 3 or 4 of the following: 1 gadolinium enhancing lesion or 9 T2 hyperintense lesions if there is no gadolinium enhancing lesion; at least 
1 infratentorial lesion; at least 1 juxtacortical lesion; at least 3 periventricular lesions; 1 spinal cord lesion can be substituted for 1 brain lesion. 
†For MRI 
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while the 2007 pediatric MS criteria demand that a minimum of 3 
months must pass between clinical events or the appearance of new 
MRI lesions
23). 
A characteristic pattern of MS on MRI would include multiple 
well-demarcated lesions in the periventricular, juxtacortical, 
infratentorial, and spinal cord white matter. These areas of 
demyelination are best recognized using T2-weighted sequences. 
T2 FLAIR image sequences are the most sensitive in this evaluation, 
especially for periventricular lesions (Fig. 3). T1-weighted sequences 
may reveal "black holes" that represent complete tissue loss resulting 
from a previous inflammatory event (Fig. 3). Enhancement of active 
areas of inflammation and blood-brain barrier compromise can be 
seen using T1 gadolinium contrast sequences. Retrospective studies 
suggest that children with MS onset have more T2 bright lesions 
in the posterior fossa and more gadolinium-enhancing lesions than 
adults
27). Further, the lesions in children were more likely to show 
reversibility on follow-up MRI than lesions in adults, suggesting 
better recovery of demyelination in children.
Detection of increased specific immunoglobulins present only 
in the CSF is often useful for supporting the diagnosis of MS in 
adult patients. A CSF sample is considered potentially positive for 
MS based upon the finding of either oligoclonal immunoglobulin 
G (IgG) bands or an increased IgG index
25). In children, the utility 
of CSF oligoclonal bands in MS diagnosis has been questioned
1). 
However, positive CSF findings, when associated with new lesions on 
follow-up MRI, can be used to make the diagnosis of MS even in the 
case of a single clinical attack
25). 
Conclusions
In the case of a child who presents with neurologic abnormalities, 
Table 5. International Panel on Multiple Sclerosis (MS) MRI Criteria for 
Dissemination in Time
First scan three or more months after onset of clinical event
A gadolinium-enhancing lesion not at the site implicated in the original 
event demonstrates dissemination in time.
If there is no enhancing lesion at this time, a follow-up scan is required 
(recommended to be performed 3 months later). A new T2 or gadolinium-
enhancing lesion on the follow-up scan demonstrates dissemination in 
time.
First scan less than three months after onset of clinical evenofft
A second scan should be performed 3 months after the onset of 
the clinical event. A new gadolinium-enhancing lesion on this scan 
demonstrates dissemination in time.
If there is no new enhancing lesion on the second scan, another follow-
up scan is required (at least 3 months after the first scan). A new T2 or 
enhancing lesion on this third scan demonstrates dissemination in time.
MRI, magnetic resonance imaging.
A C B
D E
Fig. 3. Axial T2-weighted (A) and axial fluid-attenuated inversion recovery (FLAIR) (B) images show 
multiple, ovoid shaped, hyperintense foci in the periventricular area, consistent with multiple sclerosis 
plaques. Sagittal FLAIR (C) image also shows these lesions to be radiating out from the corpus callosum. 
Axial precontrast T1-weighted (D) image shows that many of these lesions are hypointense, consistent 
with black holes. Axial postgadolinium fat saturated T1-weighted (E) image shows that some of these 
plaques enhance in a ring-like fashion consistent with active plaques. 240      YJ Lee • Acute disseminated encephalomyelitis in children
including signs of encephalitis, bacterial and viral meningitis or 
encephalitis must be considered and ruled out. In the setting of 
nonspecific CSF abnormalities and identification of white-matter 
lesions on MRI, other inflammatory demyelinating disorders 
should be considered. These include ADEM, MS, optic neuritis, 
transverse myelitis, neuromyelitis optica, and other rare disorders. 
At initial onset, ADEM and MS cannot be distinguished absolutely. 
In children, subsequent attacks of MS may not occur for months or 
years. Furthermore, a small number of children with ADEM may 
finally develop MS, but it is difficult to accurately predict in which 
patients this will occur. Therefore, prolonged follow-up is required to 
establish a diagnosis.
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